About Cellino
Cellino is a company based in Cambridge (United States) founded in 2017 by Matthias Wagner, Marinna Madrid, and Nabiha Saklayen. Cellino has raised $125 million across 6 funding rounds from investors including Khosla Ventures, Leaps by Bayer and 8VC. The company has 63 employees as of December 31, 2024. Cellino offers products and services including Nebula Platform and Autologous iPSC Therapy. Cellino operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, UCB and Rezolute, among others.
- Headquarter Cambridge, United States
- Employees 63 as on 31 Dec, 2024
- Founders Matthias Wagner, Marinna Madrid, Nabiha Saklayen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellino Biotech, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$125 M (USD)
in 6 rounds
-
Latest Funding Round
$25 M (USD), Series A
Sep 18, 2024
-
Investors
Khosla Ventures
& 6 more
-
Employee Count
63
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellino
Cellino offers a comprehensive portfolio of products and services, including Nebula Platform and Autologous iPSC Therapy.
AI-driven system for scalable biomanufacturing of personalized regenerative therapies
Treatments for degenerative diseases using patient-specific stem cells
People of Cellino
Unlock access to complete
Funding Insights of Cellino
Cellino has successfully raised a total of $125M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellino
Cellino has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Leaps by Bayer and 8VC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences sector
|
Locked | Locked | Locked | |
|
Venture capital firm investing in technology, life sciences, and related sectors.
|
Locked | Locked | Locked | |
|
Early-stage companies in science and technology are supported by Humboldt Fund.
|
Locked | Locked | Locked |
Investor details for Cellino
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellino
Investment portfolio details for Cellino
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellino
Detailed financials for Cellino
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellino Comparisons
Peer comparison for Cellino
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellino
Cellino operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, UCB and Rezolute, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
Detailed competitors of Cellino
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellino
Complete news archive for Cellino
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellino
Cellino was founded in 2017.
Cellino is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Nabiha Saklayen is the current CEO of Cellino. They have also founded this company.
Cellino is a funded company, having raised a total of $125M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Cellino is 63.
Cellino was founded in 2017 in Cambridge, United States, and operates in the biotechnology sector focused on regenerative medicine. An AI-guided laser editing platform, single-cell laser processing, and robotics are utilized to generate autologous induced pluripotent stem cells. These therapies target diseases such as Parkinsons, diabetes, and heart disease, with operations centered on advancing cell-based treatments for clinical applications.
Cellino's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Cellino offers Nebula Platform and Autologous iPSC Therapy.
Cellino has 7 investors. Key investors include Khosla Ventures, Leaps by Bayer, 8VC, Humboldt Fund, and Felicis Ventures.